{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:02:18Z","timestamp":1791349338098,"version":"4.3.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"vor","delay-in-days":1461,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1038\/ki.2013.451","type":"journal-article","created":{"date-parts":[[2013,11,20]],"date-time":"2013-11-20T13:43:58Z","timestamp":1384955038000},"page":"693-700","source":"Crossref","is-referenced-by-count":88,"title":["Sodium\u2013glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?"],"prefix":"10.1016","volume":"86","author":[{"given":"Richard E.","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2013.451_bb0010","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/phar.1303","article-title":"The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus","volume":"33","author":"Riser Taylor","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1038\/ki.2013.451_bb0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jcb.10631","article-title":"Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1)","volume":"90","author":"Zhou","year":"2003","journal-title":"J Cell Biochem"},{"key":"10.1038\/ki.2013.451_bb0020","doi-asserted-by":"crossref","first-page":"29365","DOI":"10.1074\/jbc.270.49.29365","article-title":"Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney","volume":"270","author":"You","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1038\/ki.2013.451_bb0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther"},{"key":"10.1038\/ki.2013.451_bb0030","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.lfs.2004.10.016","article-title":"SLC5A9\/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose","volume":"76","author":"Tazawa","year":"2005","journal-title":"Life Sci"},{"key":"10.1038\/ki.2013.451_bb0035","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications","volume":"75","author":"Bakris","year":"2009","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.451_bb0040","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MNH.0b013e32833bec06","article-title":"Sodium-glucose transport: role in diabetes mellitus and potential clinical implications","volume":"19","author":"Vallon","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1038\/ki.2013.451_bb0045","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocr Rev"},{"key":"10.1038\/ki.2013.451_bb0050","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/ki.1983.72","article-title":"Hemodynamically mediated glomerular injury and the progressive nature of kidney disease","volume":"23","author":"Brenner","year":"1983","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.451_bb0055","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1681\/ASN.V2111578","article-title":"Impaired myogenic responsiveness of the afferent arteriole in streptozotocin-induced diabetic rats: role of eicosanoid derangements","volume":"2","author":"Hayashi","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.451_bb0060","first-page":"F605","article-title":"Effect of exogenous and endogenous angiotensin II in the isolated perfused rat kidney","volume":"235","author":"Davalos","year":"1978","journal-title":"Am J Physiol"},{"key":"10.1038\/ki.2013.451_bb0065","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1172\/JCI112528","article-title":"Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat","volume":"77","author":"Anderson","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2013.451_bb0070","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI112521","article-title":"Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension","volume":"77","author":"Zatz","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2013.451_bb0075","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.451_bb0080","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.451_bb0085","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.451_bb0090","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","author":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","year":"1997","journal-title":"Lancet"},{"key":"10.1038\/ki.2013.451_bb0095","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1038\/ki.2013.451_bb0100","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","article-title":"Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group","volume":"36","author":"Bakris","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2013.451_bb0105","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ki.2008.145","article-title":"Tubuloglomerular feedback: mechanistic insights from gene-manipulated mice","volume":"74","author":"Schnermann","year":"2008","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.451_bb0110","series-title":"Brenner and Rector\u2019s The Kidney","first-page":"94","article-title":"The renal circulations and glomerular ultrafiltration","author":"Munger","year":"2012"},{"key":"10.1038\/ki.2013.451_bb0115","doi-asserted-by":"crossref","first-page":"F156","DOI":"10.1152\/ajprenal.00409.2012","article-title":"Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus","volume":"304","author":"Vallon","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2013.451_bb0120","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"Thomson","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1038\/ki.2013.451_bb0125","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1038\/ki.2013.451_bb0130","series-title":"Kidney Int","article-title":"Long-term randomized study (104 weeks) of dapagliflozin in patients with type 2 diabetes and moderate renal impairment who have inadequate glycemic control","author":"Kohan","year":"2013"},{"key":"10.1038\/ki.2013.451_bb0135","author":"Coelln-Hough","year":"2013","journal-title":"FDA Canagliflozin, Endocrinologic and Metabolic Drugs Advisory Committee Meeting"},{"key":"10.1038\/ki.2013.451_bb0140","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","article-title":"A role for uric acid in the progression of renal disease","volume":"13","author":"Kang","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.451_bb0145","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.451_bb0150","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/ndt\/gfq635","article-title":"Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin","volume":"26","author":"Kanbay","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2013.451_bb0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.jrn.2010.10.024","article-title":"Serum uric acid as a new player in the development of diabetic nephropathy","volume":"21","author":"Hovind","year":"2011","journal-title":"J Renal Nutr"},{"key":"10.1038\/ki.2013.451_bb0160","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2337\/dc10-0227","article-title":"High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up","volume":"33","author":"Ficociello","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2013.451_bb0165","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.2337\/db09-0014","article-title":"Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study","volume":"58","author":"Hovind","year":"2009","journal-title":"Diabetes"},{"key":"10.1038\/ki.2013.451_bb0170","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s11892-013-0381-0","article-title":"Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study","volume":"13","author":"Maahs","year":"2013","journal-title":"Curr Diab Rep"},{"key":"10.1038\/ki.2013.451_bb0175","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/HYPERTENSIONAHA.111.171488","article-title":"Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial","volume":"58","author":"Miao","year":"2011","journal-title":"Hypertension"},{"key":"10.1038\/ki.2013.451_bb0180","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1093\/ndt\/gfl325","article-title":"Effect of tranilast in early-stage diabetic nephropathy","volume":"21","author":"Soma","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2013.451_bb0185","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1159\/000064071","article-title":"Tranilast slows the progression of advanced diabetic nephropathy","volume":"92","author":"Soma","year":"2002","journal-title":"Nephron"},{"key":"10.1038\/ki.2013.451_bb0190","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.4155\/cli.11.143","article-title":"New and emerging therapies for gout","volume":"1","author":"Crittenden","year":"2011","journal-title":"Clin Investig"},{"key":"10.1038\/ki.2013.451_bb0195","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/ard.39.2.173","article-title":"Renal handling of uric acid in normal and gouty subject: evidence for a 4-component system","volume":"39","author":"Levinson","year":"1980","journal-title":"Ann Rheum Dis"},{"key":"10.1038\/ki.2013.451_bb0200","first-page":"132","article-title":"Uric acid elimination in the urine. Pathophysiological implications","volume":"147","author":"Marangella","year":"2005","journal-title":"Contrib Nephrol"},{"issue":"Pt 2","key":"10.1038\/ki.2013.451_bb0205","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/000456329202900206","article-title":"Serum urate, serum glucose and diabetes","volume":"29","author":"Whitehead","year":"1992","journal-title":"Ann Clin Biochem"},{"key":"10.1038\/ki.2013.451_bb0210","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1136\/pgmj.62.733.1001","article-title":"Serum uric acid, serum glucose and diabetes: relationships in a population study","volume":"62","author":"Cook","year":"1986","journal-title":"Postgraduate Med J"},{"key":"10.1038\/ki.2013.451_bb0215","first-page":"213","article-title":"Urate excretion during mannitol and glucose diuresis","volume":"70","author":"Skeith","year":"1967","journal-title":"J Lab Clin Med"},{"key":"10.1038\/ki.2013.451_bb0220","first-page":"188","article-title":"Renal effects of insulin in man","volume":"10","author":"Quinones-Galvan","year":"1997","journal-title":"J Nephrol"},{"key":"10.1038\/ki.2013.451_bb0225","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1152\/ajplegacy.1970.219.4.1080","article-title":"Effect of phloridzin on uric acid excretion in man","volume":"219","author":"Skeith","year":"1970","journal-title":"Am J Physiol"},{"key":"10.1038\/ki.2013.451_bb0230","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890.2011.560181","article-title":"A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials","volume":"44","author":"Musso","year":"2012","journal-title":"Ann Med"},{"key":"10.1038\/ki.2013.451_bb0235","author":"Agency"},{"key":"10.1038\/ki.2013.451_bb0240","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/j.ackd.2012.07.009","article-title":"Renal transport of uric acid: evolving concepts and uncertainties","volume":"19","author":"Bobulescu","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1038\/ki.2013.451_bb0245","doi-asserted-by":"crossref","first-page":"F527","DOI":"10.1152\/ajprenal.00134.2012","article-title":"Human SLC2A9a and SLC2A9b isoforms mediate electrogenic transport of urate with different characteristics in the presence of hexoses","volume":"303","author":"Witkowska","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2013.451_bb0250","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MNH.0b013e32832ee3de","article-title":"Solute carrier family 2, member 9 and uric acid homeostasis","volume":"18","author":"Cheeseman","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1038\/ki.2013.451_bb0255","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2013.451_bb0260","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment","volume":"32","author":"Wilding","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2013.451_bb0265","author":"Squibb"},{"key":"10.1038\/ki.2013.451_bb0270","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.ajkd.2013.03.018","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD","volume":"62","author":"Taler","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2013.451_bb0275","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/j.ajkd.2012.07.011","article-title":"Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial","volume":"61","author":"Fernandez Juarez","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2013.451_bb0280","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcjd.2013.02.055","article-title":"Type 2 diabetes,ellitis management in Canada: is it improving?","volume":"37","author":"Leiter","year":"2013","journal-title":"Can J Diabetes"},{"key":"10.1038\/ki.2013.451_bb0285","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0344-0338(80)80051-3","article-title":"Structure and function of the kidney in diabetic glomerulosclerosis: correlations between morphological and functional parametes","volume":"167","author":"Bader","year":"1980","journal-title":"Pathol Res Pract"},{"key":"10.1038\/ki.2013.451_bb0290","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0344-0338(11)80780-6","article-title":"The pathogenesis of chronic renal failure in diabetic nephropathy: investigation of 488 cases of diabetic glomerulosclerosis","volume":"187","author":"Bohle","year":"1991","journal-title":"Pathol Res Pract"},{"key":"10.1038\/ki.2013.451_bb0295","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1681\/ASN.V1061253","article-title":"Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis","volume":"10","author":"Cordonnier","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.451_bb0300","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2337\/diab.43.8.1046","article-title":"Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria","volume":"43","author":"Taft","year":"1994","journal-title":"Diabetes"},{"key":"10.1038\/ki.2013.451_bb0305","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1046\/j.1523-1755.1999.00271.x","article-title":"Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells","volume":"55","author":"Zhang","year":"1999","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.451_bb0310","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/ki.1992.14","article-title":"Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule","volume":"41","author":"Rocco","year":"1992","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.451_bb0315","first-page":"F704","article-title":"High glucose induces cell hypertrophy and stimulates collagen gene transcription in proximal tubule","volume":"259","author":"Ziyadeh","year":"1990","journal-title":"Am J Physiol"},{"key":"10.1038\/ki.2013.451_bb0320","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1046\/j.1523-1755.1998.00081.x","article-title":"Renal expression of transforming growth factor-beta inducible gene-h3 (beta ig-h3) in normal and diabetic rats","volume":"54","author":"Gilbert","year":"1998","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.451_bb0325","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1046\/j.1523-1755.1999.00721.x","article-title":"The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?","volume":"56","author":"Gilbert","year":"1999","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.451_bb0330","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1523-1755.1999.00248.x","article-title":"Renal proximal tubular cell fibronectin accumulation in response to glucose is polyol pathway dependent","volume":"55","author":"Morrisey","year":"1999","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.451_bb0335","doi-asserted-by":"crossref","first-page":"e54442","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?","volume":"8","author":"Panchapakesan","year":"2013","journal-title":"PLoS One"},{"key":"10.1038\/ki.2013.451_bb0340","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1038\/ki.2013.451_bb0345","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2337\/diab.42.4.604","article-title":"The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy","volume":"42","author":"O\u2019Brien","year":"1993","journal-title":"Diabetes"},{"key":"10.1038\/ki.2013.451_bb0350","doi-asserted-by":"crossref","first-page":"305403","DOI":"10.1155\/2008\/305403","article-title":"Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats","volume":"2008","author":"Malatiali","year":"2008","journal-title":"Exp Diabetes Res"},{"key":"10.1038\/ki.2013.451_bb0355","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/sj.bjp.0703829","article-title":"Improved diabetic syndrome in C57BL\/KsJ-db\/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095","volume":"132","author":"Arakawa","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1038\/ki.2013.451_bb0360","first-page":"169","article-title":"Tubuloglomerular feedback and the control of glomerular filtration rate","volume":"18","author":"Vallon","year":"2003","journal-title":"News Physiological Sci"},{"key":"10.1038\/ki.2013.451_bb0365","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2215\/CJN.11451210","article-title":"A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function","volume":"6","author":"Kanbay","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.451_bb0370","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11255-007-9253-3","article-title":"Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions","volume":"39","author":"Kanbay","year":"2007","journal-title":"Int Urol Nephrol"},{"key":"10.1038\/ki.2013.451_bb0375","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":"Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level","volume":"47","author":"Siu","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2013.451_bb0380","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.451_bb0385","first-page":"128","article-title":"Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients","volume":"4","author":"Momeni","year":"2010","journal-title":"Iranian J Kidney Dis"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381530363X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381530363X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T09:45:04Z","timestamp":1647423904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525381530363X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S008525381530363X"],"URL":"https:\/\/doi.org\/10.1038\/ki.2013.451","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}